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Bioactive sphingolipids including ceramides are involved in a variety of pathophysiological processes by regulating
cell death and survival. The objective of the current study was to examine ceramide metabolism in preeclampsia, a
serious disorder of pregnancy characterized by oxidative stress, and increased trophoblast cell death and autophagy.
Maternal circulating and placental ceramide levels quantified by tandem mass spectrometry were elevated in
pregnancies complicated by preeclampsia. Placental ceramides were elevated due to greater de novo synthesis via
high serine palmitoyltransferase activity and reduced lysosomal breakdown via diminished ASAH1 expression caused
by TGFB3-induced E2F4 transcriptional repression. SMPD1 activity was reduced; hence, sphingomyelin degradation by
SMPD1 did not contribute to elevated ceramide levels in preeclampsia. Oxidative stress triggered similar changes in
ceramide levels and acid hydrolase expression in villous explants and trophoblast cells. MALDI-imaging mass
spectrometry localized the ceramide increases to the trophophoblast layers and syncytial knots of placentae from
pregnancies complicated by preeclampsia. ASAH1 inhibition or ceramide treatment induced autophagy in human
trophoblast cells via a shift of the BOK-MCL1 rheostat toward prodeath BOK. Pharmacological inhibition of ASAH1
activity in pregnant mice resulted in increased placental ceramide content, abnormal placentation, reduced fetal
growth, and increased autophagy via a similar shift in the BOK-MCL1 system. Our results reveal that oxidative stress-
induced reduction of lysosomal hydrolase activities in combination with elevated de novo synthesis leads to ceramide
overload, resulting in increased trophoblast cell autophagy, and typifies preeclampsia as a sphingolipid storage
disorder.
Introduction
Sphingolipids, classically thought to be purely inert struc-
tural elements of the cell membrane, have been recognized as
bioactive signaling mediators in modulating a variety of funda-
mental cellular processes.1 In particular, ceramides (CERs) are
important signal effector molecules in the cellular response to
stress and apoptosis.2 CERs are primarily generated by de novo
synthesis in the endoplasmic reticulum (ER); however, they can
also be produced from the catabolism of complex sphingolipids
in a variety of subcellular compartments. Notably, in the lyso-
some, CER levels are dynamically regulated by a balance
between the rates of their conversion from sphingomyelin
(SM), catalyzed by SMPD1 (sphingomyelin phosphodiesterase
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1, acid lysosomal [acid sphingomyelinase]) and their break-
down into sphingosine (SPH) and fatty acyl-CoA catalyzed by
ASAH1 (N-acylsphingosine amidohydrolase [acid ceramidase]
1).3 Both ASAH1 and SMPD1 are glycoproteins synthesized in
the ER where they undergo extensive N-glycosylation, which is
essential for their transport to the acidic lysosomal compart-
ments where they are cleaved into active enzymes.3-5
Sphingolipid accumulation typifies several human disor-
ders. Niemann-Pick disease is a lysosomal storage disorder
caused by mutations in the SMPD1 gene. The lysosomal
accumulation of SM leads to organ abnormalities, pulmonary
insufficiency, and cardiovascular disease.6 Inherited deficien-
cies caused by mutations in the ASAH1 gene results in Farber
disease, a rare disorder that is characterized by lysosomal
CER accumulation causing joints and subcutaneous abnor-
malities.7 Long-chain CERs (C16 to C24) play important
roles in the induction of cell death and autophagy.2,8–10 Con-
versely, sphingosine-1-phosphate (S1P), a bioactive CER
metabolite generated by hydrolysis of CER to SPH and
its subsequent phosphorylation by sphingosine kinases, pro-
motes cell survival.11 Since CERs are the only sphingolipid
species that can be synthesized de novo while all other sphin-
golipids originate from CERs, the rheostat between CERs
and S1P is critically dependent upon the activity of regula-
tory enzymes, ceramidases, and sphingomyelinases, making
these enzymes important determinants of cell fate.9
Alterations in the rheostat between placental cell death
and survival are known contributors to improper placenta-
tion and, consequently, to the development of pregnancy-
related disorders, such as preeclampsia (PE).12 This serious
disease complicates 5% to 7% of all pregnancies and is clin-
ically characterized by the sudden onset of maternal hyper-
tension.13 In PE, the lack of remodeling of the maternal
spiral arteries by trophoblast cells causes insufficient utero-
placental circulation leading to placental hypoxia and oxida-
tive stress,14-16 which in turn is responsible for increased
trophoblast autophagy and apoptosis.17,18 Excessive tropho-
blast cell death and turnover leads to exuberant shedding
and release of syncytial debris into the maternal circulation,
which consequently contribute to the systemic vascular
endothelial injury leading to the maternal clinical symp-
toms.19 Notably, women who experience preeclampsia are at
higher risk of developing the metabolic syndrome later in
life.
While major strides have been made in understanding the
regulatory mechanism(s) of sphingolipid metabolism and
their involvement as bioactive mediators in controlling cell
fate in a variety of systems, sphingolipid metabolism and
function in the human placenta remains elusive. In this
study, we examined whether sphingolipids, in particular
CERs, are contributing to the excessive cell death in PE. We
found that the oxidative stress status characteristic of PE
causes an increase in de novo CER synthesis while decreasing
ASAH1 expression and activity, thereby favoring accumula-
tion of CERs, which contributes to increased trophoblast cell
autophagy seen in this disorder.
Results
Ceramide levels in preeclampsia
We first determined the sphingolipid levels in placentae from
PE and preterm control (PTC) pregnancies using LC-MS/MS.
Analyses revealed significant increases in various CERs (e.g. C16-
Cer(d18:1/16:0), C18-Cer(d18:1/18:0), C20-Cer(d18:1/20:0),
and C24-Cer(d18:1/24:0), but not C22-Cer(d18:1/22:0) in PE
placentae compared to PTC (Fig. 1A), while the relative abun-
dance of individual CERs (% of total) remained unchanged.
CER distribution and levels did not differ between placentae
obtained from vaginal delivery versus those from caesarian sec-
tion in both normotensive control and pathological groups (Fig.
S1A), indicating that labor had no effect on placental sphingoli-
pid levels. MALDI-MS imaging of both PE and PTC placentae
localized C16 and C24 ceramide increases primarily to the tro-
phoblast layers (Fig. 1C) and syncytial knots (Fig. 1C, right pan-
els) of PE placentae. In line with LC-MS/MS data, C22 ceramide
distributions were not different between PE and PTC placentae
(Fig. 1C). Also, phosphatidylcholine (e.g. PC-16:0/20:4) distri-
butions were similar between PE and PTC placentae. Immuno-
fluorescent staining with an anti-ceramide antibody confirmed
that CERs mainly localized to the trophoblastic layers of PE pla-
centae (Fig. 1D). Since syncytial knots originating from the tro-
phoblastic layers are typically shed in the maternal circulation,
we next examined CER levels in sera obtained from PE and PTC
pregnancies. CER levels, including C16, C18, C20, and C24,
were significantly elevated in sera of PE patients relative to those
found in control normotensive women (Fig. 1B). In contrast,
circulating S1P levels in PE women were significantly decreased
relative to controls (Fig. 1B, lower panel).
CER tissue levels are tightly regulated by their rate of synthesis
and breakdown. In order to establish the source of CER accumu-
lation, we first examined the de novo synthesis pathway. We
measured the activity of SPT (serine palmitoyltransferase), the
rate-limiting enzyme of the de novo pathway that catalyzes the
condensation of serine and palmitoyl-CoA to form 3-keto dihy-
drosphingosine (3-KDS). SPT activity was significantly increased
in PE placentae compared to both PTC and TC controls
(Fig. 2A). Moreover, sphinganine (Sa) and dihydroceramide
(DHCer), both intermediates of the de novo pathway after
3-KDS, were significantly increased in PE compared to PTC pla-
centae indicating that elevated CERs in PE are in part due to
heightened de novo synthesis (Fig. 2B).
ASAH1 expression in preeclampsia
In addition to de novo synthesis, CER levels are exquisitely
dependent upon the action of lysosomal ASAH1 and SMPD1.
Accumulation of CERs in PE suggests that the machinery involved
in CERs breakdown may potentially be altered; hence, we exam-
ined the expression of ASAH1. This enzyme hydrolyzes CERs into
SPH and free fatty acids. It is synthesized as a 55-kDa precursor
protein that is processed in the lysosomes to the active heterodi-
meric enzyme composed of an a (non-glycosylated 13 kDa) and
b (glycosylated 40 kDa) subunit.3 Western blot analysis identified
ASAH1 as a doublet of approximately 40 kDa in the placental
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lysates (Fig. 2C andD).3 Immunoblots in the presence and absence
of a competing peptide confirmed ASAH1 as a band with amolecu-
lar mass of »40 kDa corresponding to the b-subunit of the active
enzyme (Fig. 2C). ASAH1 protein levels were markedly reduced in
PE compared to PTC and TC (Fig. 2D and E). No significant
changes in ASAH1 expression between PTC and TC were found
(Fig. 2E). Moreover, ASAH1 enzyme activity was significantly
reduced in PE placentae compared to those from PTC and TC
placentae (Fig. 2F). In line with the protein data, qPCR revealed a
significant decrease in ASAH1 mRNA levels in PE compared to
PTC (Fig. 2G). In silico promoter analysis of the ASAH1 gene did
not reveal any hypoxic response binding sites, suggesting no direct
regulation by HIF1A; however, the promoter contains several puta-
tive binding sites for E2F transcription factors upstream from the
translation start site corresponding to nucleotides ¡399 to ¡392
and ¡261 to ¡254. Hence, we examined E2F1 and E2F4 protein
Figure 1 (See previous page). Sphingolipid levels are increased in preeclamptic placentae. CER levels measured by LC-MS/MS in placental tissue (A) and
sera (B) from PE women compared to normotensive PTC. Numbers indicate fatty acid chain length of CERs with d18:1 sphingosine backbone (PE, n D 45;
PTC, P D 40 *P<0.05). (B, lower panel) S1P content in sera from PE and PTC women. (C, left panels) Spatial localization of CERs in placentae from PE and
PTC using MALDI-MS imaging (MSI). Representative images of C16:0, C22:0; C24:0 CER and phosphatidylcholine PC-16:0/20:4 distributions in PE and PTC
sections. BF: bright field image. (C, right panels) H&E and MSI of C16:0 CER. Merged image (M) of H&E and MSI shows C16:0 CER distribution in PE placen-
tal villi. Intensities of ions based on the intensity scale provided. (D) Spatial localization of ceramide immunoreactivity in placental sections from PE and
PTC placentae (ST, syncytiotrophoblast cells). Ceramide (red) and nuclei counterstained with DAPI (blue). Bar: 1cm in BF; Bar: 50 mm in H&E.
Figure 2. The de novo ceramide synthesis is increased in preeclampsia while acid ceramidase expression and activity is reduced. (A) SPT activity in PE
and PTC placentae. (B) Sphinganine (Sa) and dihydroceramide (DHCer24) content in PE vs. PTC placentae (PE, n D 45; TC, n D 40; *P < 0.05). (C) Western
blot analysis of ASAH1 following incubation with a competing peptide (CP) for ASAH1 antibody in PTC placental lysates. (D and E) ASAH1 protein expres-
sion in PE vs PTC placentae (PE, n D 23; PTC, n D 15; TC, n D 11 *P<0.0015). (F) ASAH1 enzyme activity in PE placentae compared to PTC and TC placen-
tae. (G) ASAH1mRNA expression in PE vs. PTC placentae (PE, n D 9; PTC, n D 10, *P< 0.002).
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expression. E2F4 repressor levels were increased in PE vs. PTC pla-
centae while E2F1 activator levels were unchanged (Fig. 3A). ChIP
analysis revealed increased binding of E2F4 repressor to the ASAH1
promoter in PE vs. PTC placentae (Fig. 3B). RNAi knockdown of
E2F4 repressor increased ASAH1 gene and protein expression in
trophoblastic JEG3 cells (Fig. 3C andD), supporting direct regula-
tion of ASAH1 expression by this transcription factor. Further-
more, we found that TGFB1/3 upregulated E2F4 expression in
JEG3 cells that was partially abolished with SMAD2 RNAi
(Fig. 3E), suggesting that the increase in E2F4 is downstream of
the activatedHIF/TGFB3 axis in PE.20
Oxidative stress and ASAH1 expression
PE is a pathology associated with placental hypoxia and oxida-
tive stress.15,16,21 We next assessed the ceramide profile in villous
explants treated with and without sodium nitroprusside (SNP), a
nitric oxide donor that also activates the Fenton reaction and
induces a state of oxidative stress through generation of reactive
oxygen species.21 LC-MS/MS analysis showed that 5.0 mM
SNP treatment led to significant increases in C16 and C18 CERs
compared to untreated control explants maintained at standard
(20% O2) conditions, while no differences were found for C20
and C24 CERs (Fig. 3F, left panel) as well as for sphingomyelin
(Fig. S1C). Increased hydrogen peroxide release following treat-
ment with SNP in villous explants confirmed that SNP induced
oxidative stress (Fig. S1D). Exposure of JEG3 cells to SNP also
resulted in elevated CER levels (not shown). To determine
whether oxidative stress affects ASAH1 expression villous
explants were treated with SNP. As can be seen in Figure 3G,
exposure to 2.5 and 5.0 mM SNP resulted in a significant
Figure 3. Oxidative stress reduces acid ceramidase expression and impinges on ceramide levels. (A) Representative immunoblots for E2F4 and E2F1 in PE
and PTC placentae. (B) ChIP analysis of E2F4 binding to ASAH1 promoter in PE (PE; n D 6 in triplicate) vs. PTC (PTC; n D 6 in triplicate) placentae. Data
expressed as % of ASAH1 qPCR of total input DNA; ChIP with nonimmune IgG served as negative control, *P<0.05 vs PTC). (C) AC mRNA expression in
E2F4 siRNA-treated JEG3 cells (n D 3, *P<0.05). (D) E2F4 and ASAH1 protein expression in E2F4 siRNA-treated JEG3 cells. (E) Representative immunoblots
for E2F4 and phosphorylated pSMAD2 in JEG3 cells following treatment with TGFB1/3 with and without SMAD2 RNAi. (F) Ceramide levels in explants (n
D 6 *P<0.05) following SNP exposure. (G) ASAH1 protein expression in villous explants after SNP treatment.
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decrease in ASAH1 b-subunit expression when compared to
untreated controls. Similarly to villous explants, JEG3 cells
exposed to SNP exhibited reduced active ASAH1 expression (not
shown).
Disruption in SMPD1 processing and function
in preeclampsia
Activation of lysosomal SMPD1 is thought to be a major cel-
lular response to stress leading to the production of CERs.22 Lipi-
domic analysis revealed no differences in total SM in PE
compared to PTC placental tissue (Fig. S1B). These data argue
against an activation of SMPD1 and are more indicative of a
reduced activity in PE. To investigate this possibility, we deter-
mined the expression and activity of SMPD1. Although no dif-
ferences in SMPD1 transcripts between PE and PTC were found
(data not shown), SMPD1 protein levels, specifically the 75-kDa
precursor protein, were markedly increased in PE placentae
(Fig. 4A). SMPD1 contains 6 N-linked oligosaccharide chains,
which are known to affect trafficking, processing, folding, and
activity of this enzyme.4 To examine whether the glycosylation
status of SMPD1 was altered in PE placenta, SMPD1 was immu-
noprecipitated followed by immunoblotting with concanavalin A
(detects N-glycans such as a-D-Man and a-D-Glc). Markedly
more N-linked glycans were found in SMPD1 of PTC vs PE pla-
centae (Fig. 4A, lower panel), suggesting that N-glycosylation of
SMPD1 is altered in PE. We then examined SMPD1 activity
and observed a significant decrease in SMPD1 activity in PE pla-
centae when compared to PTC (Fig. 4B). Together, the findings
suggest that SMPD1 processing is altered in placentae from PE
pregnancies, resulting in a reduction of its activity and favoring
SM instead of CER formation.
Oxidative stress and SMPD1 expression, trafficking,
and activity
To determine if the oxidative stress status typical of PE
pathologies was a contributing factor to altered SMPD1 expres-
sion and processing, we treated placental villous explants and
JEG3 cells with SNP and observed a dose-dependent increase in
SMPD1 protein expression. Similar to PE placentae, SNP
increased the 75-kDa SMPD1 precursor levels (Fig. 4C and D)
and significantly reduced SMPD1 activity in both explants and
JEG3 cells (Fig. 4C and D, lower panels). We then examined
SMPD1 subcellular localization in JEG3 cells following SNP
treatment. In vehicle-treated (control) cells positive SMPD1 sig-
nal was detected in the cytoplasm where it colocalized with
LysoTracker

Red, indicating its presence in the lysosomal com-
partment (Fig. S2, left panel). In contrast, SNP treatment
resulted in colocalization of SMPD1 with the ER marker CALR
(calreticulin; Fig. S2, right panel), suggesting that SNP-induced
oxidative stress affects the intracellular shuttling of the SMPD1
precursor. Since TGFB3 is elevated in PE,20,23 we examined
whether SMPD1 was regulated by TGFBs. Similarly to PE and
SNP, TGFB3 and to a lesser extent TGFB1 increased SMPD1
75-kDa precursor levels while reducing its active 70-kDa form in
JEG3 cells (Fig. 4E). Conversely, inhibition of TGFB signaling
using SB-431542, an established blocker of TGFBR1/ALK5, sig-
nificantly increased SMPD1 activity in villous explants (Fig. 4F).
Lysosomal accumulation of CERs and SMs in preeclampsia
Since the aforementioned experiments were performed with
whole-tissue lysates, we next examined CER metabolism in lyso-
some-enriched fractions of PE and PTC placentae as well as vil-
lous explants treated with and without SNP. Purity of lysosomal
fractions was validated with LAMP1 (endo/lysosome marker)
and CANX (calnexin; ER-microsome marker) (Fig. 5A) as well
as by activity measurements of ACP2 (acid phosphatase 2, lyso-
somal) (Fig. 5B). Lysosomal fractions purified from PE tissue
had significant elevated levels of C16 and C18 CER (Fig. 5C) as
well as of SM:16 and SM:18 (Fig. 5C, lower panel). No signifi-
cant changes in CERs were detected in the microsomal fractions
purified from PE placentae relative to PTC (Fig 5C, right panel).
Western blot analysis showed striking changes in subcellular dis-
tribution of SMPD1 between PE and PTC samples. Active
SMPD1 levels were reduced in lysosomes from PE placentae
compared to PTC, while the 75-kDa precursor was markedly
increased in the microsomal fractions from PE placentae, in line
with impairment in subcellular trafficking of this enzyme
(Fig. 5D). Both immature (53 kDa) and mature (40 kDa)
ASAH1 levels were markedly decreased in microsomes and lyso-
somes, respectively, from PE placentae compared to PTC, in
agreement with reduced gene expression (Fig. 5D). Immunoflu-
orescence analysis using a specific CER antibody in conjunction
with LAMP1 confirmed that CERs specifically accumulated in
the lysosomes of trophoblastic layers of PE placentae (Fig. 5E).
To exclude that the lysosomal CERs increase in PE placentae was
due to an increased breakdown of glycosylceramides we measured
lysosomal glucosyl- and galactosyl-ceramide levels as well as lyso-
somal GBA (glucosidase, b, acid) activity (Fig. S1E and F). Both
glycosylceramides increased in PE vs. PTC (Fig. S1E); however,
GBA activity did not change (Fig. S1F). Moreover, glycosylcera-
mides were approximately 50-fold less abundant than lysosomal
ceramides. Thus, it is unlikely that they markedly contributed to
the increase in lysosomal ceramides in PE placentae. Lysosomal
analysis of villous explants after SNP treatment resulted in similar
ceramide increases as seen in PE placental lysosomes, suggesting
that oxidative stress altered lysosomal ceramide metabolism
(Fig. 5F).
ASAH1 inhibition in pregnant mice
To establish the impact of ASAH1 function in placentation,
we administered 2 different ASAH1 inhibitors, namely Ceranib-
2 and D-NMAPPD, to pregnant mice starting at E7.5. While no
changes in maternal weight were observed, both inhibitors
reduced fetal and placental weights at E13.5 (Fig. 6A). The fetal
weight reductions were in the range of severely growth restricted
human fetuses (approximately 15%) at 28 to 32 wk of gestation.
In addition, striking abnormalities in placental architecture were
observed in Ceranib-2-treated animals including compaction and
reduced branching of the labyrinthin zone as well as reduction of
the junctional zone and diminished vascularization (Fig. 6B and
C). Similar changes in placental architecture were observed with
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D-NMAPPD (Fig. S4). Importantly, inhibition of ASAH1
activity in pregnant mice led to increases in long-chain CERs in
the murine placentae, similar to that seen in the human PE
placentae (Fig. 6D). These data further underscore the impor-
tance of examining altered ASAH1 expression during placental
development and in disease.
Figure 4. Expression, glycosylation, and activity of acid sphingomyelinase are altered in preeclampsia. (A) Upper panel: Protein expression of SMPD1 (70-
kDa active and 75-kDa precursor protein) in PE compared to PTC placentae. Lower panel: Immunoprecipitation of SMPD1 from PE placental lysates fol-
lowed by western blot using concanavalin A (ConA) in PE vs PTC placentae. (N represents immunoprecipitation with nonimmune IgG control). (B)
SMPD1 enzyme activity in PE compared to PTC placentae (PE, n D 6; PTC, n D 6 *P<0.05). (C) SMPD1 protein expression (upper panel) and enzyme activ-
ity (lower panel) in human villous explants following exposure to SNP (n D 5 *P<0.02). (D) Protein expression (upper panel) and enzyme activity (lower
panel) in JEG3 cells treated with SNP (n D 6 *P<0.05). (E) SMPD1 and phosphorylated pSMAD2 in JEG3 cells following treatment with TGFB1 and TGFB3.
(F) SMPD1 enzyme activity in villous explants after exposure to the TGFBR1/ALK5 inhibitor SB-431542 (n D 3, *P < 0.05). RFU, relative fluorescence units.
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CER and autophagy in JEG3
cells
CERs, known inducers of
apoptosis, have recently also
been implicated in autophagy, a
catabolic lysosomal degradative
process that links networks of
cellular metabolism and death.24
Since apoptosis and autophagy
are disrupted in preeclamp-
sia,17,18,25 it is plausible that ele-
vated CERs seen in PE trigger
these events. To determine CER
effects on trophoblast cell fate,
we treated JEG3 cells with a syn-
thetic C16 CER. Exposure of
JEG3 cells to C16 CER for 6 h
caused a significant increase in
the expression of autophagic
marker LC3B-II when compared
to cells treated with control
(100% ethanol) vehicle (n D 6,
P D 0.039) (Fig. 7A, upper
panel). Levels of SQSTM1/p62,
an established marker of auto-
phagic flux involved in LC3
associations to ubiquitinated
substrates, were also significantly
increased in JEG3 cells following
a 6-h exposure to C16 CER (n
D 6, P D 0.0329) (Fig. 7A,
lower panel). After 24 h of C16
CER treatment LC3B-II and
SQSTM1 expression disap-
peared while cleaved CASP3
(caspase 3, apoptosis-related cys-
teine peptidase) appeared, sug-
gesting an early induction of
autophagy followed by a later
occurrence of apoptosis
(Fig. 7A, bottom panel). To fur-
ther dissect the role of CERs in
autophagy we used 2-oleoyletha-
nolamine (2-OE), a well-known
inhibitor of ASAH1 activity.26
We reasoned that ASAH1 inhi-
bition in JEG3 cells would
increase CERs, thereby mimick-
ing the scenario found in PE.
Western blot analysis showed
that treatment of JEG3 cells with
2-OE for 6 h resulted in a signif-
icant increase in the expression
of both autophagic markers:
LC3B-II (n D 6, P D 0.042) and
SQSTM1 (n D 6, P D 0.0118)
Figure 5. Ceramide accumulates in lysosomal fractions in preeclampsia. (A and B) PE and PTC placental tis-
sue were subjected to subcellular fractionation. Lysosomal (L) fractions were enriched in LAMP1 (A) and
ACP2/acid phosphatase activity (B) whereas microsomal (M) fractions contained CANX (A). (C upper panel)
CER levels in lysosomal (L) and microsomal (M) subfractions isolated from PE and PTC placentae (PE, n D 5;
PTC, n D 5 *P<0.05). (C lower panel) SM content in L subfractions from PE and PTC placentae. (D) SMPD1
and ASAH1 protein expression in L and M subfractions from PE and PTC placentae. (E) Immunofluorescence
analysis of CER and LAMP1 of placental sections from PTC and PE to visualize CER compartmentalization to
lysosomes. (F) CER levels in L subfractions from villous explants treated with SNP or control vehicle. CANX,
calnexin.
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Figure 6. Addition of Ceranib-2 or D-NMAPPD alters murine placental development. (A) Fetal (left) and placental (right) weights from CD1 mice injected
with ASAH1 inhibitor, ceranib-2 or D-NMAPPD (20 mg/kg), or DMSO vehicle (DMSO, n D 9; Ceranib-2, n D 13; D-NMAPPD, n D 8, 2 separate litters,
*P<0.05). (B) H&E staining of placental sections from mice injected with ceranib-2 vs DMSO. (C) Placental sections stained with angiogenesis marker,
CD34, from ceranib-2-injected mice compared to DMSO (D D decidua, S D spongy layer, L D labyrinth). (D) Placental ceramide levels in mice injected
with either ceranib-2 or D-NMAPPD compared to DMSO. (DMSO, n D 7; Ceranib-2, n D 13; D-NMAPPD, n D 4 *P < 0.05). (E) MCL1, BOK and LC3B-II
expression in pregnant mice injected with D-NMAPPD compared to DMSO vehicle.
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(Fig. 7B). We next exam-
ined the expression of
BECN1, a BH3-only
BCL2 family member that
is central in the crosstalk
between apoptosis and
autophagy. Treatment of
JEG3 cells with 2-OE
resulted in a significant
increase in BECN1 protein
expression (n D 6, P D
0.0423) (Fig.7B). Since
autophagy proceeds
through fusion of autopha-
gosomes with lysosomes
when degradation of cyto-
plasmic constituents is
completed, we analyzed
lysosomal activity using
LysoTracker

Red, a dye
taken up by activated lyso-
somes. Increased lysosomal
activity was detected in
JEG3 cells after 6 h treat-
ment with C16 CER (Fig.
S3). Additionally, 2-OE
exposure led to a concentra-
tion-dependent increase in
lysosomal activity in JEG3
cells (Fig. S3). TEM of
JEG3 cells treated with
C16 CER showed a
marked number of vacuo-
lar-like structures typifying
autophagosomes (indicated
by black arrowheads)
(Fig. 7C). In addition, the
C16 CER-induced increase
in the number of lysosomes
noted with TEM (indicated
by black arrows) is consis-
tent with the
LysoTracker

Red findings.
TEM also revealed the
presence of autophago-
somes and autolysosomal
structures (indicated by
black arrowheads) in cells
exposed to 2-OE while
cytoplasmic vacuolization
was absent in vehicle
(DMSO)-treated control
cells (Fig. 7C, bottom
panels). To establish auto-
phagic flux, we examined
LC3B-II expression in
Figure 7. Ceramide triggers autophagy in JEG3 cells. (A) LC3B-II, SQSTM1 and cleaved CASP3 (Cl¡CASP3) protein
expression in JEG3 cells treated with C16 CER or vehicle (C). (B) Autophagy markers, LC3B-II, BECN1, and SQSTM1, in
JEG3 cells cultured with ASAH1 inhibitor 2-OE (25 mM or 100 mM) or control vehicle (C). (C) Representative transmis-
sion electron micrographs of JEG3 cells treated with C16 CER or 100 mM 2-OE compared to control vehicle. Autoph-
agy is shown by increased number of lysosomes (arrows) and formation of autophagosomal structures
(arrowheads). N, nucleus. Scale bars: 2 mm. (D) JEG3 cells treated with C16 CER or 2-OE were labeled with
LysoTracker

Red and stained for LC3B. LC3B (green), LysoTracker

Red and nuclear DAPI (blue). (E) LC3B-II expres-
sion in JEG3 cells treated with C16 CER (upper panel) or 2-OE (middle panel) in the presence and absence of bafilo-
mycin A1 (Baf A1) or of 3-methyladenine (3-MA; lower panel). (F) MCL1 and BOK expression in JEG3 cells treated
with 20 mM or 50 mM C16 CER (upper panel) or 25 or 50 mM 2-OE (lower panel).
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JEG3 cells cultured in the presence or absence of C16 CER or
100 mM 2-OE following treatment with bafilomycin A1
(BafA1). Treatment of JEG3 cells with C16 CER and 2-OE
resulted in an increased colocalization of LC3B-II with
LysoTracker

Red relative to vehicle-treated control cells, sup-
porting autolysosomal fusion and completion of autophagy
(Fig. 7D). Moreover, both C16 CER and 2-OE treatment
increased LC3B-II expression, an effect that was further aug-
mented by BafA1indicating that flux through the autophagic
pathway was inhibited (Fig. 7E). In addition, treatment of JEG3
cells with 3-methyladenine (3-MA; 5 mM), a PtdIns3K and
PI3K inhibitor that blocks early events of autophagy, abrogated
the C16 CER-induced effect on LC3B-II expression (Fig. 7E,
lower panel) demonstrating suppression of autophagy. Thus,
CERs directly or indirectly via inhibition of ASAH1 activity pro-
mote an autophagic response. We have recently reported that
increased autophagy found in PE is due to an altered BOK-
MCL1 (BCL2-related ovarian killer-myeloid cell leukemia 1)
rheostat.18 Hence, we investigated whether CERs influence the
BOK-MCL1 system. Exposure of JEG3 cells to either C16 CER
or 2-OE resulted in a marked decrease of prosurvival MCL1 and
increase in prodeath BOK (Fig. 7F). Notably, administration of
ASAH1 inhibitor D-NMAPPD to pregnant mice at E7.5 led to
a similar alteration in the placental BOK-MCL1 rheostat at
E13.5, favoring BOK and thereby augmenting autophagy as
shown by increased LC3B-II production (Fig. 6E).
Discussion
Herein, we demonstrate for the first time that changes in SPT,
ASAH1, and SMPD1 activities offset the delicate balance
between CERs and its metabolites in PE. In combination with
an increased de novo CER synthesis via SPT activation, reduced
ASAH1 expression together with diminished activity result in ele-
vated CER levels, particularly in the trophoblastic layer and syn-
cytial knots of PE placentae. SMPD1 activity was reduced in PE
placentae and, therefore, SM degradation to CER via this enzyme
did not contribute to the increase in CER. No alteration in lyso-
somal degradation of glycosylceramides was observed between
PE and PTC placentae, ruling out that their breakdown contrib-
uted to the elevated lysosomal CER levels in PE. Pharmacological
inhibition of ASAH1 activity in pregnant mice increases placental
CERs and negatively affects placental weight and development
similar to that seen in human PE pathology. Using human JEG3
choriocarcinoma cells and placental villous explants we further
demonstrate that oxidative stress conditions, typical of PE
pathology, are responsible for decreased ASAH1 expression and
impaired N-glycosylation of SMPD1, preventing its intracellular
trafficking and activation. Also, we provide evidence that TGFB3
via E2F4 transcriptional repressor is responsible for downregula-
tion of ASAH1 expression while oxidative stress-induced changes
in SMPD1 trafficking and activity are directly mediated via
TGFB3. As a result, CERs accumulate and trigger autophagy by
shifting the BOK-MCL1 rheostat toward cell death-inducing
BOK. Hence, in PE, oxidative stress favors CER accumulation
thereby contributing to the increased placental cell death found
in this disease.17,18,27
Sphingolipid accumulation due to genetic alterations in their
regulatory enzymes characterizes various lysosomal sphingolipid
storage disorders in humans, including Niemann-Pick28 and
Farber diseases.9 Our finding of reduced ASAH1 transcription in
conjunction with CER accumulation in lysosomes from PE pla-
centae identifies preeclampsia as a new sphingolipid storage dis-
order, which results from the oxidative stress milieu typical of
this pathology.16,21 There is increasing support for a role of pla-
cental-derived circulating factors in the onset of the maternal
endothelial dysfunction (i.e., increased hypertension) in pregnan-
cies associated with PE.15 Our data demonstrate that both pla-
centa and sera of PE women exhibited increased levels of specific
CERs. Hence, it is plausible that increased CERs found in the
circulation of women affected by PE may be, in part, of placental
origin. Our observation that CERs were primarily elevated in the
trophoblastic layers and syncytial knots of preeclamptic villi
underscores this possibility as these structures are shed in the cir-
culation.15 Elevation of vascular CERs in spontaneously hyper-
tensive rats leads to vasoconstriction29 and humans with essential
hypertension have increased plasma CER levels compared to nor-
motensive patients.30 Hence, elevation of CERs in maternal sera
may contribute to the hypertensive phenotype characteristic of
PE.
CER accumulation causes cell death in cystic fibrosis and can-
cer.10,31,32 Furthermore, it has been reported that CERs are
important regulators of tumor cell death following exposure to
stress stimuli33,34 and changes in sphingolipid metabolism
impact on pancreatic b-cell function.35 Our in vivo and in vitro
findings of CERs and cell death are in agreement with these pre-
vious observations. Notably, we established a critical role for
CERs in placental autophagy, a cellular event that in some
instances functions as an alternative cell death pathway.10 CERs
have been shown to trigger autophagy by activating the MAPK8/
JNK1 (mitogen-activated protein kinase 8) pathway thereby free-
ing and allowing BECN1 to perform its role in the initiation of
the autophagic response.36 Similarly, we found that inhibition of
the ASAH1 enzyme with 2-OE in JEG3 cells, led to increased
expression of proteins involved in the induction of this catabolic
pathway, including BECN1, SQSTM1, and LC3B-II. It is likely
that this increase in autophagy is due to the accumulation of
CERs since newly synthesized CERs are not sufficiently degraded
by ASAH1 in the presence of 2-OE. Our finding of increased
autophagy in JEG3 cells after C16 CER exposure supports this
idea. We also demonstrate that CERs alter the BOK-MCL1
rheostat in JEG3 cells in favor of BOK, which we have shown to
enhance autophagy in PE.18
Autophagy can serve as a stress adaptation to avoid cell death;
however, excessive autophagy can bring to cellular demise.10 Our
in vitro findings indicate rapid activation of autophagy upon
C16 CER treatment. This is in line with a previous report show-
ing that exogenous C16 CER acts as an inducer of autophagy in
HCT116 human colon carcinoma cells.37 Hence, CER-induced
autophagy in trophoblast cells may be an attempt by the cells to
swiftly respond to CER accumulation. Previous studies have
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shown that accumulation of CERs, DHCers, and SPH in the
autolysosome can cause membrane destabilization resulting in
the release of cathepsins leading to activation of CASP3 and sub-
sequent apoptosis.9 In line with these observations we found acti-
vation of CASP3 following 24-h treatments with C16 CER,
which may be indicative of autophagy progressing into cell death.
Thus, CER may gauge the level of cell injury and depending on
downstream factors determines specific biological outcomes.
ASAH1 is a lipid hydrolase that directly regulates CER metab-
olism by catalyzing its degradation into SPH and fatty acid.3
ASAH1 is essential for mammalian development as Asah1 defi-
ciency in mice results in embryonic lethality due to increased
pools of CERs.38 Other studies have shown that ASAH1 is over-
expressed in prostate cancer, which may be a compensatory
mechanism to lower CER levels, thereby providing protection
from cell death.39 At the transcriptional level, ASAH1 is regulated
by a variety of transcription factors;40 however, little is known
about the role of hypoxia or oxidative stress on ASAH1 gene
expression. Herein, we show that ASAH1 expression and activity
is decreased in preeclampsia, a disorder associated with oxidative
stress. Imposing an environment of hypoxia/oxidative stress on
placental cells using low oxygen and SNP caused similar effects
on CERs and ASAH1 protein expression as those observed in PE
placentae. Our observations of elevated E2F4, but not E2F1, lev-
els and augmented E2F4 binding to the ASAH1 promoter in pre-
eclampsia as well as E2F4 siRNA knockdown stimulation of
ASAH1 expression, support the idea of transcriptional repression
of ASAH1 expression by E2F4 in preeclampsia. Together with
our observation of TGFB3 inducing E2F4 expression, these find-
ings provide the first evidence that hypoxia/oxidative stress via
TGFB3 and subsequently, E2F4, has a detrimental effect on
ASAH1 expression, thereby contributing to increased levels of
CERs found in preeclampsia.
In the present study, we show that ASAH1 inhibition in preg-
nant mice using 2 different inhibitors increases placental CERs.
Specifically long-chain CERs (C22 and C24) were elevated. In
contrast, PE placentae exhibit significant increases in C16 and
C18 CER compared to age-matched control placentae. Compari-
son of CER composition of normal murine and human placentae
revealed that the murine placenta is enriched in C16 CER while
C24 CER is the predominant CER in the human placenta
(Table S1). This suggests that particular CERs may have diverse
functions during placental development in different species.
Intriguingly, ASAH1 inhibition during pregnancy in mice led to
reduced fetal and placental growth, abnormal placental develop-
ment including impaired vascularization as well as altered BOK-
MCL1 expression and increased autophagy, all characteristics of
PE pathology.12,17,18,41 These findings strongly suggest that
reduced ASAH1 expression in PE placentae contributes to CER
accumulation, thereby influencing placental cell fate and devel-
opment via the BOK-MCL1 system.
SMPD1 is another key enzyme in generating CERs in
response to cellular stress.42 Previous studies have shown that
increased SMPD1 activity triggered by hypoxic conditions con-
tributes to CER generation and consequently to the apoptotic
response in neuronal cells.43 In contrast, we observed a
downregulation of SMPD1 activity in PE placentae. Following
synthesis in the ER, SMPD1 undergoes extensive post-transla-
tional modification during its transport to the lysosomes where it
becomes active. Six N-glycosylation sites are essential for the traf-
ficking, processing, folding, and activity of this enzyme.3,4 In the
present study, we provide the first evidence that N-glycosylation
of SMPD1 is impaired in PE placentae. Hypoxia affects key
enzymes involved in glycosylation, including glucosyltransferases
and sugar transporters.44 Indeed, we observed that SNP-induced
oxidative stress led to a buildup of SMPD1 precursor in the ER
and impaired activity of the enzyme in a similar fashion as that
seen in PE, suggesting that N-glycosylation of SMPD1 is affected
by oxidative stress. Various hypoxic (oxidative stress) responses in
PE are mediated via the HIF1A-TGFB3 axis.20,45 Our finding of
SMPD1 precursor accumulation and reduced activity in the pres-
ence of TGFB1/3 suggests that the activated HIF1A-TGFB3 axis
in PE is responsible for the observed N-glycosylation changes of
SMPD1 leading to reduced shuttling to the lysosomes and there-
fore activity. Thus, elevated CER levels in PE are not due to
increased SM degradation via SMPD1.
Our data infer that the CERs in PE placentae are not originat-
ing from SM but are generated de novo. In line with a heightened
flux through the de novo pathway we observed increased SPT
activity and high levels of Sa and DHCers in PE placentae. Acti-
vation of the de novo pathway in PE led to an elevation in Golgi-
associated CER but not ER-associated CER (preliminary data
not shown). No significant increase in the total concentration of
SM was noted. Parallel accumulation of CER and SM as a result
of various stressors has been reported.9 Likewise, increased levels
of SMs have been found in Wharton jelly, the gelatinous connec-
tive tissue that surrounds the umbilical cord, from preeclamptic
mothers.46 It is plausible that SGMS/sphingomyelin synthase
activity is reduced in PE placentae, which would explain the
absence of an increase in total SM.
In conclusion, our results support the idea that the rheostat
between CERs and its metabolites governs trophoblast cell fate
and that both hypoxia and SNP-induced oxidative stress impinge
on sphingolipid homeostasis. In PE placentae, reduced ASAH1
expression and activity, induced by the oxidative stress via
HIF1A and subsequently TGFB3 and E2F4, together with an
elevated de novo CER synthesis favors an elevation in CERs,
which in turn alters the BOK-MCL1 rheostat leading to aug-
mented autophagy and cell death typical of this disorder.
Materials and Methods
Placental tissue and sera collection
Informed consent was obtained from each individual. Tissue
and serum collection was carried out in agreement with collabo-
rating institutions’ ethics guidelines (ethics guidelines of the Uni-
versity of Toronto’s Faculty of Medicine and Mount Sinai
Hospital) by Biobank of Mount Sinai Hospital and by the O.I.
R.M Sant’ Anna Hospital, University of Turin, Italy in accor-
dance with the Helsinki Declaration of 1975. First trimester
human placental tissues (5 to 8 wk of gestation, n D 24) were
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obtained at once following elective termination of pregnancies.
The PE group (PE, nD 68) was selected on the basis of American
College of Obstetrics and Gynecology clinical and pathological
criteria.47 Placental tissues obtained from age-matched preterm
control (PTC, n D 64) and from term control (TC, n D 23)
pregnancies deliveries from healthy pregnancies with normally
grown fetuses that did not have signs of PE or other placental
dysfunctions were included as controls. Serum samples were
obtained prior delivery from women exhibiting clinical signs of
early onset PE (PE, n D 10) and from normotensive PTC, n D
10. Patients’ information and clinical parameters are outlined in
Table 1.
Mouse experiments
CD1 mice were obtained from Charles River (St. Constant,
QC). Animal studies were conducted abiding by the criteria
established by the Canadian Council for Animal Care and
approved by the Animal Care and Use Committee of the Hospi-
tal for Sick Children, Toronto, ON. Ceranib-2 and D-
NMAPPD injections: Timed pregnant CD1 mice were intraperi-
toneally injected daily starting at E7.5 with either ceranib-2
(20 mg/kg; Cayman Chemical, 11092) or D-NMAPPD
(20 mg/kg; Cayman Chemical, 10006305). Both ASAH1 inhibi-
tors were dissolved in DMSO and mice injected with DMSO (as
per body weight) only were used as controls. At E13.5 placentae
and fetuses were microdissected, weighed and gross morphology
assessed. Placental tissue was then snap frozen for biochemical
analysis or fixed in 4% paraformaldehyde for histology.
Histology
Placentae were sectioned and stained with Harris’ haematoxy-
lin and eosin. Adjacent sections were probed with rat anti-CD34
antibody (Abcam, ab8158).
Mass spectral analysis
Placental tissues and sera from PE and PTC pregnancies as
well as JEG3 choriocarcinoma cells and human villous explants
treated with and without SNP (Sigma, 228710) or cultured at
3% or 21% oxygen were processed for lipid extraction. Lipid
extraction was performed according to Bligh and Dyer.48 Follow-
ing extraction, sphingolipids were separated using high perfor-
mance liquid chromatography (LC) and then analyzed by
tandem mass spectrometry (MS/MS) at the Analytical Facility
for Bioactive Molecules of the Hospital for Sick Children, Tor-
onto, ON (see detailed procedures in the online Supplemental
Materials).
MALDI-mass spectral imaging
Placental tissues from PE and PTC pregnancies were proc-
essed for MALDI-spectrometry imaging. A time-of-flight tandem
mass spectrometer (AB SciexTOF/TOFTM 5800 System, AB
SCIEX, Vaughan, ON) was used to acquire the images (see
detailed procedure in the online Supplemental Materials).
First trimester villous explant and cell line cultures
Chorionic villous explant and human choriocarcinoma JEG3
cells cultures were performed as previously described.20,49 Briefly,
small fragments of placental villi were dissected and cultured in
serum-free DMEM/F12 (GIBCO-BRL, 11039-021), supple-
mented with 10,000 units/ml of penicillin/streptomycin. Villous
explants were placed at 37C in either standard culture condition
(5% CO2 in 95% air) or kept in an atmosphere of 3% O2/93%
N2/5% CO2. Human choriocarcinoma JEG3 cells seeded at a
density of 1.5 £ 105 cells/well into 6-well plates were maintained
at 37C in standard conditions and cultured in EMEM media
(ATCC, 30-2003) supplemented with 10% heat-inactivated fetal
bovine serum.
SNP and TGFB treatments: JEG3 cells and human villous
explants were treated with and without either SNP (2.5, 5.0 and
10 mM) or TGFB1 and TGFB3 (5 to 10 ng/ml, recombinant
human TGFB1 (R&D Systems, 420-B3) and TGFB3 (R&D
Systems, 243-B3) for 24 h. Cells were collected in RIPA buffer
solution for western blotting or fixed in 4% paraformaldehyde to
perform immunofluorescence analysis. Explants were washed in
cold PBS (phosphate buffered saline; 137 mM NaCl, 2 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and snap frozen for
protein extraction. SNP induced oxidative stress was confirmed
by Amplex Red Hydrogen Peroxide/Peroxidase Assay kit (Life
Technologies, A22188).
C16-ceramide and 2-oleoylethanolamine treatments: JEG3 cells
were treated with and without 2-oleoylethanolamine (25 to
100 mM 2-OE; Invitrogen, 0383) dissolved in DMSO or
C16CER (20 to 50 mM C16 CER; Enzo Life Sciences, BML-
SL115) dissolved in 100% ethanol. After 6 and 24 h of treat-
ment, cells were collected for either western blotting or fixed in
4% paraformaldehyde for immunofluorescence analysis.
Subcellular fractionation
Subcellular fractions were prepared by differential centrifuga-
tion. Briefly, placenta tissues and JEG3 cells treated with SNP
Table 1. Clinical parameters of the study population
Preterm
(n D 64)
Preeclampsia
(n D 68)
Term
(n D 23)
Mean gestational
age (wk)
31 §3 29.3 §2 38.4 §0.6
Blood pressure
(mm Hg)
Sys: 117.2 §4 Sys: 169.6 §13 Sys: 111 §5
Dias: 68.7 §5 Dias: 105.3 §10 Dias: 67.6 §5
Proteinurea
(g/24 h)
Absent 3.2 §1.5 Absent
Fetal sex M: 55.9% M: 63.5% M: 80%
F: 44.1% F: 36.5% F: 20%
Fetal weight (g) 1618.4 §388 1249.5 §423 3712 §232
AGA: 81%
IUGR: 19%
Mode of delivery CS: 44.5% CS: 84.2% CS: 83%
VD: 55.5% VD: 15.8% VD: 17%
Data represented are mean § SEM.
IUGR, intrauterine growth restriction.
AGA, appropriate for gestational age.
CS, elective caesarian section delivery.
VD, vaginal delivery with labor.
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were homogenized in cold buffer (0.25 M sucrose, 1 mM EDTA
in 10 mM Tris-HCl, pH 7.4) and subjected to a series of centri-
fugations to obtain pure lysosomal and microsomal fractions.
Homogenates were first centrifuged at 1,000 £ g for 10 min after
which the resulting supernatant fractions were spun at 12,000 £
g for 10 min. The subsequent supernatant fractions were then
centrifuged at 25,000 £ g for 15 min to pellet lysosomes, while
the resulting supernatant fractions were subjected to a 105,000
£ g centrifugation for 60 min to spin down microsomes. All cen-
trifugations were performed at 4C. The lysosomal and micro-
somal fractions were then analyzed by western blotting for the
presence of lysosomal (LAMP1) and microsomal (CANX)
markers and subjected to extraction for lipid analysis. In addi-
tion, to further validate the purity of lysosomal fractions, ACP2/
acid phosphatase (a lysosomal enzyme) activity was assayed by
incubating lysosomal and microsomal fractions as well as total
homogenate with citrate buffer containing 5.5 mM p-nitrophe-
nylphosphate, for 30 min at 37C. Reactions were stopped with
addition of 0.05 M NaOH and formation of para-nitrophenol
(yellow at alkaline pH) was measured at 405 nm.
RNA analysis
Real-time PCR analysis using specific Taqman primers and
probes was performed as previously described.14 In brief, RNA
was extracted from frozen placental tissue using an RNeasy Mini
Kit (Qiagen, 74134). All samples were treated with DNase I to
eliminate genomic DNA contamination followed by reverse tran-
scription using random hexamers (Applied Biosystems,
N8080127) and amplified by 20 cycles of PCR (5 min at 95C,
cycle: 30s at 95C, 30 s at 55C and 1.5 min at 72C). Analysis
was performed using the DNA Engine Opticon 2 System (Bio-
Rad Canada, Mississauga, ON) as previously described.12 Taq-
man Universal Master Mix and specific Taqman primers and
probe for SMPD1, ASAH1, and 18S were purchased from ABI
as assays-on-demand for human genes. Data were normalized
against expression of 18S rRNA using the 2DDCt formula as pre-
viously described.12
Antibodies, HRP substrates, and western blot analysis
Western blotting was performed using tissue and cell lysates
from PTC and PE placentae and JEG3 cells as previously
described.12 Antibodies against ACTB (actin, b) (I-19, sc-1616,
goat [WB 1:1000]), ASAH1 (T-20, sc-28486, goat [IF 1:200,
WB 1:350]), E2F1 and E2F4 (sc-193 and sc-866, rabbit
[WB1:500], MCL1 (sc-819, rabbit; WB 1:500), SMPD1 (H-
181, sc-11352, rabbit [IF 1:200, WB 1:350]), and SQSTM1 (G-
10, sc-28359, mouse monoclonal [WB 1:500]) were purchased
from Santa Cruz Biotechnology. Rabbit anti-BECN1 (3495S,
[WB 1:1000]), cleaved CASP3 (9661S, [1:1000]) and LC3B
(2775S, [WB 1:1000]) antibodies were obtained from Cell Sig-
naling Technology. CALR/calreticulin (FMC 75, ab22683,
mouse monoclonal [IF 1:2000]) and rat anti-CD34 (MEC 14.7,
ab8158, [IHC 1:25]) were purchased from Abcam. Mouse
monoclonal anti-CANX/calnexin (AB2301, [WB 1:1000]) and
rabbit polyclonal anti-LAMP1 (AB2971, [WB 1:1000]) were
purchased from Millipore. Rabbit polyclonal anti-BOK was
purchased from Abgent (AP16794, WB 1:500). Monoclonal
anti-ceramide mouse IgM (MAB-0013 [IF: 1:200]) was pur-
chased from Glycobiotech. Secondary antibodies were horserad-
ish peroxidase-conjugated donkey anti-goat, goat anti-rabbit,
goat anti-mouse IgG (Santa Cruz Biotechnology, sc-2020, sc-
2004, sc-2005); Alexa Fluor 594: donkey anti–rabbitIgG
(A21207), Alexa Fluor 594: goat-anti-mouse IgM [m chain]
(A-21044) and Alexa Fluor 488: donkey anti-rabbit IgG
(A21206) [IF 1:200, Invitrogen] and rabbit anti-rat IgG, biotin
conjugated (Vector Labs, BA-2020). Biotinylated concanavalin A
(C2272, [WB: 3mg/mL]) and streptavidin-peroxidase (S5512)
were purchased from Sigma Aldrich.
Western blotting was performed using tissue and cell lysates
from PTC and PE placentae and JEG3 cells as previously
described.12 Primary antibodies were used in the dilutions stated
above. Following incubation with HRP-conjugated secondary
antibodies, membrane blots were visualized using enhanced
chemiluminescence (PerkinElmer Inc., NEL103001EA) and
imaged on X-ray film (GE Healthcare). All western blots were
confirmed for equal protein loading by probing for ACTB. For
quantification purposes, bands of interest were digitized for anal-
ysis using a CanoScanLiDE20 image scanner (Canon Canada
Inc.). Quantification of western blots was accomplished by densi-
tometry using Image Quant 5.0 software (Molecular Dynamics).
Immunoprecipitation analysis
Placental tissue lysates were precleared using a combination of
protein A-agarose (10 mL; Santa Cruz Biotechnology, sc-2001)
and protein G-agarose (10 mL; Santa Cruz Biotechnology, sc-
2002). Lysates were then incubated overnight with antibodies
against SMPD1. Nonimmune rabbit IgG (Santa Cruz Biotech-
nology, sc-2027) was used as a negative control. The immuno-
precipitated lysates were subsequently immunoblotted for
SMPD1. SMPD1 N-linked oligosaccharide chains were detected
using biotinylated concanavalin A with stepavidin-peroxidase.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using tissue lysates from PTC and PE
placentae as previously described.50 Briefly, tissues were fixed in
formaldehyde, lysed in lysis buffer (10 mM Tris, 10 mM NaCl,
0.2% Nonidet P-40 [Sigma, N6507], pH 8.0 containing prote-
ase inhibitors [Roche, 11873580001] and PMSF [Sigma,
P7626]), and nuclei were collected by centrifugation. Nuclei
were then lysed in ice-cold nuclei lysis buffer (50 mM Tris,
10 mM EDTA, 1% sodium dodecyl sulfate [SDS; Wisent, 880
550-CL]), 10 mM sodium butyrate (Sigma, B5887), protease
inhibitors, 50 mg/ml PMSF, pH 8.1), sonicated and precleared
with protein G-coated agarose beads (Santa Cruz Biotechnology,
sc-2002). Equal aliquots of precleared chromatin samples were
incubated overnight with specific rabbit anti-E2F4 or nonspecific
rabbit IgG at 4C. An additional aliquot of chromatin sample,
20% of the volume of other aliquots (input), was saved for the
subsequent PCR analysis. Immune complexes collected on pro-
tein G-coated agarose beads were eluted and incubated at 65C
with RNaseA (Abcam, ab52579) in 0.3 M NaCl. Samples were
digested with proteinase K (Abcam, ab51501) and
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immunoprecipitated DNA was purified by extraction with phe-
nol/chloroform followed by ethanol precipitation. Purified
immunoprecipitated DNA and input DNA were resuspended in
water and amplified by PCR using primers corresponding to the
human ASAH1 promoter region (EpiTect ChIP qPCR primer
assay for human ASAH1, SABiosciences, A Qiagen 334471).
SPT activity
SPT activity was determined according to a modified method
of R€utti et al.51 Placental tissues were homogenized in lysis buffer
(50 mM HEPES-NaOH, pH 8, 1 mM EDTA pH 8, 0.1% w/v
sucrose monolaurate (Sigma, 84110). Lysates were then centri-
fuged at 2500 £ g for 2 min and supernatant aliquots (100 100
mg mu;g of total protein) were incubated at 37 8C in 10 mM L-
serine, 0.25 mM palmitolyl Co-A (Avanti Polar Lipids,
870716), 0.25 mM pyridoxal 5’-phosphate (total volume
200 ml; Sigma, P9255) with and without 1 mg/mL myriocin
(negative control; Sigma, D3314). After 30 min, the reaction
was stopped by addition of 500 mL ice-cold methanol. Standards
(3-keto dihydrosphingosine (3-KDS; Matreya LLC, 1876) in
200 mL lysate buffer) and samples were spiked with 10 ng sphin-
gosine-d7 (internal standard/IS; Avanti Polar Lipids, 860657)
and lipids were extracted by adding 800 mL ultrapure water, 500
mL methanol, and 2 mL of chloroform. The chloroform layer
was collected, the aqueous layer was re-extracted and the chloro-
form layer was recombined with the previous extract. Extracts
were taken to dryness under stream of nitrogen, reconstituted in
100 mL 9:2 ethanol/water C 0.2% formic acid and analyzed by
LC-MS/MS. HPLC was performed using an Agilent 1200 Series
binary pump and auto-sampler. The analytical column was a
Kinetex XB C18 (50 £ 3.0 mm, 2.6 6 mm mu;m particle size)
from Phenomenex. The isocratic HPLC mobile phases consisted
of 40:60 A:B (A) D 0.2% formic acid in water and (B) D 0.2%
formic acid in acetonitrile. A flow rate of 0.6 mL/minute was
used. The HPLC system was coupled to an AB SCIEX API 4000
triple-quadrupole mass spectrometer. Positive ESI multiple reac-
tion monitoring (MRM) was used. The product 3-KDS was
quantified by monitoring the 300.4/270.4 m/z transition and
that of the IS (307.4/289.5 m/z) and using the area ratios of the
standards to create a standard curve by which the concentrations
of 3-KDS in the samples were calculated.
ASAH1 activity
ASAH1 (N-acylsphingosine amidohydrolase [acid cerami-
dase] 1) activity was measured by the conversion of C12:0 cer-
amide to lauric acid according to a modified method of Realini
et al.52 Placental tissues were homogenized in cold buffer
(50 mM Tris-HCl, 0.32 M sucrose [Sigma, S-9378], pH 7.4),
centrifuged at 800 £ g for 15 min at 48C to remove debris and
supernatants were then centrifuged for 30 min at 12,000 £ g at
48C. Resulting pellet fractions were resuspended in PBS and sub-
jected to 2 freeze-thaw cycles at ¡808C. Samples were then cen-
trifuged at 100,000 £ g for 1 h at 48C and protein content in
the supernatant fractions was quantified. Supernatant aliquots
(10 mg of protein) were then mixed with assay buffer, pH 4.5
(100 mM sodium citrate dihydrate, 150 mM sodium chloride,
100 mM sodium phosphate monobasic, 0.1% v/v IGEPAL CA-
630 [Sigma, I-8896], 3 mM DTT) to a final volume of 190 uL.
Ceramide 12:0 (Avanti Polar Lipids, 860512) was then added to
a final concentration of 50 mM and samples were incubated for
1 h at 378C. Activity was stopped with 600 mL ice cold 2:1 chlo-
roform:methanol. Internal standard (100 ng heptadecanoic acid;
Sigma, H3500) was added and samples were centrifuged at 800
£ g for 10 min. The organic layer was transferred into conical
glass tubes and dried under a gentle stream of nitrogen at 378C.
Residues were reconstituted in 200 mL methanol and analyzed
by LC-MS/MS. A standard curve of lauric acid (Cayman Chemi-
cal, 10006626) was also prepared ranging from 0.5 to 250 mM.
HPLC was performed using an Agilent 1200 Series binary
pump, and auto-sampler. The analytical column was Kinetex XB
C18 (50 £ 3 mm, 2.6 6 mm mu;m particle size) from Phenom-
enex. The HPLC mobile phases consisted of A) 5 mM ammo-
nium acetate, 0.25% acetic acid and B) 5 mM ammonium
acetate in methanol, 0.25% acetic acid. A flow rate of 0.6 mL/
minute was used and samples were eluted using a gradient start-
ing at 60% B, holding for 1 min, and then increasing to 100% B
over 1.5 min, holding at that condition for 1 min, and then
returning to the starting conditions, for a total of 5 min. The
HPLC system was coupled to an AB SCIEX API5000 triple-
quadrupole mass spectrometry. Negative ESI multiple reaction
monitoring (MRM) was used. Lauric acid was quantified by
monitoring the 199.17/199.17 m/z transition and that of the IS
(269.3/269.3 m/z) and using the area ratios of the standards to
create a standard curve by which the concentrations of lauric acid
in the samples were calculated.
SMPD1 activity
SMPD1/acid sphingomyelinase (sphingomyelin phosphodies-
terase 1, acid lysosomal) activity was assessed in placental tissue
lysates using an Echelon SMPD1 assay kit according to the man-
ufacturer’s protocol (Echlon Bioscience, K-3200). Briefly, 50 mg
of protein lysate from placental tissues and 30 mg of protein
lysate from JEG3 cells and human villous explants were used to
determine SMPD1 activity. After incubation with the SMPD1
substrate at 37C for 3 h SMPD1 activity was analyzed using a
96-well fluorescence microtiter plate reader (Tecan Infinite
M200, Tecan US Inc., Morrisville, NC) at 360 nm excitation
and 460 nm emission. The enzyme activity was calculated from
the slope of the graph of intrinsic fluorescence plotted against
time.
GBA activity
GBA (glucosidase, b, acid) activity was measured by incubat-
ing 2 to 4 mg of lysosomal protein at 45C in a 50 mM sodium
acetate buffer (pH 5.0) containing 2 mM p-nitrophenyl-b-D-
glucopyranoside (Sigma, N7006). After a 10-min incubation,
the reaction was stopped with addition of 1M Na2CO3 and for-
mation of para-nitrophenol (yellow at alkaline pH) was measured
at 405 nm. Specific activity was defined as mmol of para-nitro-
phenol formed per mg of protein per min.
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Hydrogen peroxide/peroxidase assay
Villous explants were treated with SNP (5.0 mM) or vehicle.
After 24 h condition media was collected. H2O2 from condition
media was detected according to the manufacturer’s instruction
(Amplex RedHydrogen Peroxide/Peroxidase Assay kit; Life Tech-
nologies, A22188). Briefly, H2O2 standard curve was prepared by
serially diluting a 20 mM stock solution of H2O2. Condition
media was loaded into a 96-well microplate. A working solution of
100 mM Amplex red reagent and 0.2 U/mL horeseradish peroxi-
dase was prepared and added to the condition media followed by a
30-min incubation. Fluorescence was measured using a microplate
reader (Tecan Infinite M200) in the range of 530 to 560 nm and
fluorescence emission detection at»590 nm.
Immunofluorescence staining
Immunofluorescence staining was performed as previously
described.17 In placental tissue sections, antigen retrieval was per-
formed using 10 mM sodium citrate, pH 6.0, followed by treatment
with Sudan Black (Sigma, 199664; 0.3% Sudan Black in 70% etha-
nol) to quench endogenous fluorescence. JEG3 cells were permeabi-
lized with 0.2% Triton X-100 (Bioshop, TRX506) in PBS. Both
placental sections and cells were preincubated at room temperature
with 5% normal horse serum (Sigma, H0146) diluted in PBS to
block nonspecific binding sites. Cells were then incubated with pri-
mary antibodies diluted in 5% blocking serum and antibody diluent
(0.4% sodium azide, 0.625% gelatin [Sigma, G8150] in PBS) over-
night at 4C. For negative controls, the primary antibody was
replaced by a corresponding concentration of nonimmune mouse
(Santa Cruz Biotechnology, sc-2025), goat (Santa Cruz Biotechnol-
ogy, sc-2028) or rabbit IgG. Cells/sections were treated with DAPI
(40,6-diamino-2-phenylindole) for nuclear detection. Fluorescence
images were viewed and captured using the DeltaVision Deconvolu-
tion microscopy with z-stacking (GE Healthcare, Baie d’Urfe, Que-
bec). LysoTracker

Red (Invitrogen, L7528) was used to monitor
lysosomal activity. LysoTracker

Red dye at a concentration of
1 mM inDMSOwasmixed with culturemedia to a final concentra-
tion of 50 nM. Following treatment with 2-OE or C16 CER, cells
were incubated in this mixture for 1 h at 37C. Following 4% form-
aldehyde fixation, cells were washed in PBS and nuclei were subse-
quently counterstained with 40,6-diamidino-2-phenylindole (DAPI;
Sigma, D9542). To determine ASAH1 and SMPD1 lysosomal
localization following SNP hindrance, JEG3 cells treated for 1 h
with LysoTracker

Red (50 nM). Cells were subsequently fixed and
incubated with primary antibody against ASAH1 or SMPD1 over-
night and secondary detection was performed as described above.
Fluorescence images were viewed and captured using the Delta
VisionDeconvolutionmicroscopy with z-stacking.
Transmission electron microscopy
JEG3 cells were treated either with DMSO (vehicle for
2-OE), 100 mM 2-oleoylethanolamine (2-OE), 100% ethanol
(vehicle for C16 CER) or 50 mM C16CER were processed for
TEM analysis. Samples for TEM were fixed in 2% glutaralde-
hyde in 0.1 M sodium cacodylate buffer, rinsed in buffer, post-
fixed in 1% osmium tetroxide in buffer, dehydrated in a graded
ethanol series followed by propylene oxide, and finally embedded
in Quetol-Spurr resin (Electron Microscopy Scieneces, 20440).
Sections 100-nm thick were cut on an RMC MT6000 ultrami-
crotome, stained with uranyl acetate and lead citrate, and viewed
with an FEI Tecnai 20 TEM (Hillsboro, Oregon).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4
software. For comparison of data between 2 groups we used the
paired or unpaired Student t test, where applicable. For compari-
son between multiple groups, one-way analysis of variance
(ANOVA) with post-hoc Dunnett or Newman-Keuls test was
performed, where applicable. Statistical significance was defined
as P < 0.05. Results are expressed as the mean § SEM.
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